Mid-size Drugs Based on Peptides and Peptidomimetics A New Drug Cate
This brief describes studies conducted by the authors on mid-size drugs utilizing peptides and peptidomimetics, and on the development of anti-HIV agents. Peptides are important biological molecules and have various physiological actions. Peptide-based dr
- PDF / 4,463,866 Bytes
- 113 Pages / 439.37 x 666.142 pts Page_size
- 108 Downloads / 138 Views
Hirokazu Tamamura Takuya Kobayakawa Nami Ohashi
Mid-size Drugs Based on Peptides and Peptidomimetics A New Drug Category
SpringerBriefs in Pharmaceutical Science & Drug Development
SpringerBriefs in Pharmaceutical Science & Drug Development present concise summaries of cutting-edge research and its applications in the fields of the pharmaceutical and biotechnology industries. Featuring compact volumes of 50 to 125 pages, the series covers a range of content from professional to academic. Typical topics might include: • A timely report of state-of-the art analytical techniques • A bridge between new research results, as published in journal articles, and a contextual literature review • A snapshot of a hot or emerging topic • An in-depth case study or clinical example • Practical information and background to allow researchers to transition into new areas SpringerBriefs in Pharmaceutical Science & Drug Development will allow authors to present their ideas and findings to their scientific and research communities quickly and will allow readers to absorb them with minimal time investment. Both solicited and unsolicited manuscripts are considered for publication in this series.
More information about this series at http://www.springer.com/series/10224
Hirokazu Tamamura Takuya Kobayakawa Nami Ohashi •
Mid-size Drugs Based on Peptides and Peptidomimetics A New Drug Category
123
Hirokazu Tamamura Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering Tokyo Medical and Dental University Tokyo Japan
Nami Ohashi Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering Tokyo Medical and Dental University Tokyo Japan
Takuya Kobayakawa Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering Tokyo Medical and Dental University Tokyo Japan
ISSN 1864-8118 ISSN 1864-8126 (electronic) SpringerBriefs in Pharmaceutical Science & Drug Development ISBN 978-981-10-7690-9 ISBN 978-981-10-7691-6 (eBook) https://doi.org/10.1007/978-981-10-7691-6 Library of Congress Control Number: 2017962023 © The Author(s) 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the edito
Data Loading...
